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Induction of proteasome expression in skeletal muscle is
attenuated by inhibitors of NF-kB activation
SM Wyke1, ST Russell1 and MJ Tisdale*,1
1Pharmaceutical Sciences Research Institute, Aston University, Birmingham B4 7ET, UK
The potential for inhibitors of nuclear factor-kB (NF-kB) activation to act as inhibitors of muscle protein degradation in cancer
cachexia has been evaluated both in vitro and in vivo. Activation of NF-kB is important in the induction of proteasome expression and
protein degradation by the tumour factor, proteolysis-inducing factor (PIF), since the cell permeable NF-kB inhibitor SN50 (18 mM)
attenuated the expression of 20S proteasome a-subunits, two subunits of the 19S regulator MSS1 and p42, and the ubiquitin-
conjugating enzyme, E214k, as well as the decrease in myosin expression in murine myotubes. To assess the potential therapeutic
benefit of NF-kB inhibitors on muscle atrophy in cancer cachexia, two potential inhibitors were employed; curcumin (50mM) and
resveratrol (30mM). Both agents completely attenuated total protein degradation in murine myotubes at all concentrations of PIF, and
attenuated the PIF-induced increase in expression of the ubiquitin–proteasome proteolytic pathway, as determined by the
‘chymotrypsin-like’ enzyme activity, proteasome subunits and E214k. However, curcumin (150 and 300 mg kg
1) was ineffective in
preventing weight loss and muscle protein degradation in mice bearing the MAC16 tumour, whereas resveratrol (1 mg kg1)
significantly attenuated weight loss and protein degradation in skeletal muscle, and produced a significant reduction in NF-kB DNA-
binding activity. The inactivity of curcumin was probably due to a low bioavailability. These results suggest that agents which inhibit
nuclear translocation of NF-kB may prove useful for the treatment of muscle wasting in cancer cachexia.
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Loss of skeletal muscle mass in cancer patients has a negative
influence on prognosis, resulting in asthenia, immobility and early
death. While lysosomal and calcium-activated proteases play some
role in the breakdown of myofibrillar proteins, the ubiquitin–
proteasome proteolytic pathway is considered to be the predomi-
nant system in both experimental models of cancer cachexia
(Attaix et al, 1999) and in cancer patients (Bossola et al, 2003).
Proteins to be degraded are marked by the covalent attachment of
a polyubiquitin chain, which is recognised by the 19S subunits of
the 26S proteasome, a multisubunit cylindrical structure composed
of a and b units, with the proteolytic enzymes situated on the inner
surface of the cylinder on the b-subunits. Expression of the
enzymes of ubiquitin conjugation and proteasome subunits are
upregulated in cancer cachexia (Lorite et al, 1998). Knowledge of
the mechanism for the regulation of proteasome expression in
cancer cachexia should facilitate the design of effective inhibitors.
Muscle mass in cancer cachexia is strongly regulated by a
tumour produced sulphated glycoprotein, proteolysis-inducing
factor (PIF), which inhibits protein synthesis and stimulates
protein degradation (Lorite et al, 1997). The effect on protein
degradation is due to an increased gene and protein expression of
the key components of the ubiquitin–proteasome proteolytic
pathway (Lorite et al, 2001). In murine myotubes, induction of
proteasome expression by PIF is associated with an increased
DNA-binding activity of the transcription factor NF-kB, concomi-
tant with a transient decrease in cytosolic levels of the NF-kB
inhibitor protein, I-kBa (Whitehouse and Tisdale, 2003). Degrada-
tion of I-kBa is initiated by phosphorylation of two serine residues
(32 and 36) in the N-terminal portion of the molecule, which
results in ubiquitination and subsequent degradation by the 26S
proteasome (Brockman et al, 1993). Phosphorylation is mediated
by a high molecular weight complex (I-kB kinase or IKK), which in
the case of PIF is probably activated by protein kinase C (PKC)
(Smith et al, 2004). The polyunsaturated fatty acid, eicosapentae-
noic acid (EPA), which has been shown to preserve muscle mass in
cancer cachexia by downregulating the increased expression of the
ubiquitin–proteasome pathway (Whitehouse et al, 2001), pre-
vented PIF-induced nuclear migration of NF-kB, loss of I-kBa and
the increase in proteasome expression (Whitehouse and Tisdale,
2003). This suggests that agents that interfere with activation of
NF-kB may be useful in preventing muscle protein degradation in
cancer cachexia.
Two potential agents have been studied to verify this hypothesis.
Curcumin, a natural product from tumeric, prevents activation of
NF-kB by blocking phosphorylation and subsequent degradation
of I-kBa and has been shown to increase the rate and extent of
muscle regeneration after trauma (Thaloor et al, 1999). Resvera-
trol, a natural phytoalexin found in red wine also inhibits NF-kB
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activation through inhibition of IKK (Holmes-McNary and
Baldwin, 2000). Both agents have been evaluated for their ability
to inhibit PIF-induced proteasome expression in vitro and as
anticachectic agents in mice bearing the MAC16 tumour, which
induces profound cachexia involving wasting of skeletal muscle
(Beck and Tisdale, 1987).
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Figure 1 Effect of SN50 (18 mM) (lanes 6–10) and the cell permeable inactive control peptide SN50M (18 mM) (lanes 1–5) on PIF-induced expression of
20S proteasome a-subunits (A), MSS1 (B), p42 (C), E214k (D) and myosin (E) in murine myotubes 24 h after addition of PIF, as determined by Western
blotting. The peptides were added 2 h prior to PIF. An actin loading control is shown in (F). Myotubes were treated with 0 (lanes 1 and 6), 2.1 (lanes 2 and
7), 4.2 (lanes 3 and 8), 10.5 (lanes 4 and 9) and 16.8 nM PIF (lanes 5 and 10). A densitometric analysis presenting the average of three separate blots is shown
for each Western blot. The densitometric analysis of the proteasome 20S a-subunits is for the two major bands in the absence (’, ) and presence (&, )
of SN50 (18 mM). Values for the control peptide are shown as solid boxes and for SN50 as open boxes. Differences from control are indicated as a, Po0.05,
b, Po0.01 and c, Po0.001, while differences from the control peptide in the presence of SN50 are shown as d, Po0.05, e, Po0.01 and f, Po0.001.
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MATERIALS AND METHODS
Animals
Pure strain male NMRI mice (average weight 25 g) were obtained
from our own inbred colony and were fed a rat and mouse
breeding diet (Special Diet Services, Witham, UK) and water ad
libitum. Animals were implanted with the MAC16 tumour s.c. in
the flank by means of a trochar, selecting from donor animals with
established weight loss (Beck and Tisdale, 1987). Animals with an
average weight loss of 5% (10–12 days after transplantation) were
randomised to receive resveratrol (1 mg kg1 body weight
dissolved in DMSO : PBS (1 : 20)) i.p. daily, while controls received
solvent alone. Body weight and tumour volume were measured
daily. Tumour volume was calculated from the formula:
Length (width)2/2. All animal experiments followed a strict
protocol, approved by British Home Office, and the ethical
guidelines that were followed meet the standards required by the
UKCCR guidelines (Workman et al, 1998). Animals were
terminated by cervical dislocation and the soleus muscles were
quickly dissected out, together with intact tendons, and main-
tained in isotonic ice-cold saline before determination of protein
degradation. For protein degradation, muscles were fixed by their
tendons at approximately resting length in 3 ml of oxygenated
(95% oxygen : 5% carbon dioxide) Krebs –Henseleit Buffer (pH
7.4) containing 5 mM glucose and 0.5 mM cycloheximide. The
protein degradation rate was determined by the release of tyrosine
(Waalkes and Udenfriend, 1957) over a 2 h period.
Materials
Foetal calf serum (FCS), horse serum (HS) and Dulbecco’s
modified Eagle’s medium (DMEM) were purchased from Life
Technologies (Paisley, UK). Mouse monoclonal antibodies to 20S
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Figure 2 (A) Effect of curcumin (50 mM) on total protein degradation in
the presence of PIF for 24 h, as measured by the release of
[3H]phenylalanine. Myotubes were incubated with PIF alone (E) or
pretreated with curcumin ( ) 2 h prior to the addition of PIF. Differences
from 0 nM PIF are indicated as b, Po0.01 and c, Po0.001, while differences
in the presence of curcumin are indicated as d, Po0.05 and f, Po0.001.
n¼ 9. The experiment was repeated three times. (B) Chymotrypsin-like
enzyme activity in soluble extracts of murine myotubes after treatment
with PIF alone for 24 h (E), or after treatment with PIF in the presence of
curcumin ( ). The experiment was repeated three times (n¼ 9). The
symbols for the differences are the same as in (A).
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Figure 3 Effect of curcumin on PIF-induced expression of 20S
proteasome a-subunits (A) and E214k (B) in murine myotubes, determined
by Western blotting. Cells were incubated for 24 h with 0 (lanes 1 and 6),
2.1 (lanes 2 and 7), 4.2 (lanes 3 and 8), 10.5 (lanes 4 and 9) or 16.8 nM PIF
(lanes 5 and 10) in the absence (lanes 1–5) or presence (lanes 6–10) of
curcumin (50 mM) added 2 h prior to PIF. An actin loading control is shown
in (C). Densitometric analysis of three separate blots is shown under each
Western blot. Differences from 0 nM PIF are shown as a, Po0.05, b,
Po0.01 and c, Po0.001, while differences in the presence of curcumin are
indicated as d, Po0.05, e, Po0.01 and f, Po0.001.
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proteasome a-subunits, MSS1 and p42 were purchased from
Affiniti Research Products (Exeter, UK), while mouse monoclonal
antibody to myosin heavy chain was from Novocastra (Newcastle,
UK) and to I-kBa was from Biomol Research Laboratories Inc.
(PA, USA). Rabbit polyclonal antisera to mouse actin was from
Sigma Aldridge (Dorset, UK) and to ubiquitin conjugating enzyme
(E214k) was a gift from Dr Simon Wing, McGill University,
Montreal, Canada. Peroxidase-conjugated rabbit anti-mouse anti-
body and peroxidase-conjugated goat anti-rabbit antibody were
purchased from Dako Ltd. (Cambridge, UK). Hybond A nitro-
cellulose membranes and enhanced chemiluminescence (ECL)
development kits were from Amersham International (Bucks, UK).
Electrophoretic-mobility shift (EMSA) gel shift assay kits were
from Panomics (California, USA). SN50 and its inactive congener
(Lin et al, 1995) were purchased from Calbiochem (Nottingham,
UK). Curcumin was purchased from Sigma Aldridge (Dorset, UK),
and resveratrol from Biomol Research Laboratories Inc. (PA,
USA).
Purification of PIF
Proteolysis-inducing factor was purified from solid MAC16
tumours excised from mice with a weight loss between 20 and
25% as previously described (Todorov et al, 1996a; Whitehouse
and Tisdale, 2003). Tumours were homogenised in 10 mM Tris-
HCl, pH 8.0, containing 0.5 mM phenylmethylsulphonyl fluoride,
0.5 mM EGTA and 1 mM dithiothreitol (DTT) at a concentration of
5 ml g1 tumour. The supernatant obtained after addition of
ammonium sulphate (40% w v1) was subjected to affinity
chromatography using anti-PIF monoclonal antibody coupled to
a solid matrix. The immunogenic fractions were concentrated and
used for further studies. The purity of the PIF was confirmed by
polyacrylamide gel electrophoresis and immunoblotting. This
showed a band for PIF at Mr 24 000, sometimes accompanied by
an albumin-bound band at Mr 69 000 (Todorov et al, 1996b). No
other bands were apparent.
Cell culture
C2C12 myoblasts were propagated in DMEM supplemented with
10% FCS, glutamine and 1% penicillin– streptomycin under an
atmosphere of 10% CO2 in air at 371C. Myotubes were formed by
allowing confluent cultures of myoblasts to differentiate in DMEM
containing 2% HS with medium changes every 2 days. Differentia-
tion was complete in 5 –7 days, and the cells remained viable for a
further 4– 5 days.
Measurement of protein degradation
This was determined as described previously (Whitehouse and
Tisdale, 2003) by prelabelling cells for 24 h with L-[2,63H]pheny-
lalanine (0.67 mCi mmole1) followed by extensive washing in PBS
and further incubation for 2 h in DMEM without phenol red until
no more radioactivity appeared in the supernatant. Protein
degradation was determined by the release of [2,63H]phenylalanine
into the medium after 24 h in the presence of various concentra-
tions of PIF together with 2 mM cold phenylalanine to prevent
reincorporation of radioactivity in the cells.
Measurement of proteasome activity
‘Chymotrypsin-like’ enzyme activity was determined fluorimetri-
cally by the method of Orino et al (1991) by the release of
aminomethyl coumarin (AMC) from the fluorogenic peptide
succinyl-LLVY-AMC. This method has been described previously
for C2C12 myotubes (Whitehouse and Tisdale, 2003). Activity was
measured in the absence and presence of the specific proteasome
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Figure 4 Effect of curcumin administered p.o. daily at 150 ( ) or 300
(B) mg kg1 in DMSO : PBS (1 : 1000), as previously used (Busquets et al,
2001), compared with DMSO : PBS (1 : 1000) alone (E) on weight loss in
mice bearing the MAC16 tumour over a 5 day period. There was a
significant weight loss for all groups at day 5 (Po0.001), but there was no
difference in weight loss between groups.
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Figure 5 (A) Effect of resveratrol (30 mM) on total protein degradation
in murine myotubes in the presence of PIF for 24 h, as measured by the
release of [3H]phenylalanine. Myotubes were incubated with PIF alone (E)
or preincubated with resveratrol 2 h prior to addition of PIF and maintained
in the culture medium over the 24 h period ( ). Differences from control
are indicated as b, Po0.01 and c, Po0.001, while differences in the
presence of resveratrol are indicated as f, Po0.001. The experiment was
repeated three times (n¼ 9). (B) Chymotrypsin-like enzyme activity in
soluble extracts of murine myotubes after treatment with PIF alone for 24 h
(solid boxes) or after treatment with PIF in the presence of resveratrol
(30 mM) (open boxes). The symbols for the differences are the same as in
(A). The experiment was repeated three times (n¼ 9).
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inhibitor lactacystin (10 mM). Only lactacystin suppressible activity
was considered to be proteasome specific.
Western blot analysis
Myotubes were incubated with various concentrations of PIF as
depicted in the figure legends, after which the medium was
removed and the cells were washed with PBS and scraped from the
plastic surface. They were then sonicated at 41C in 500–2000 ml of
20 mM Tris-HCl, pH 7.5, 2 mM ATP, 5 mM MgCl2 and 1 mM DTT.
Samples of cytosolic protein (5–30 mg), formed by centrifugation
at 18 000 g for 5 min, were resolved on 12% sodium dodecylsul-
phate, polyacrylamide gels (SDS/PAGE) and transferred to 0.45 mm
nitrocellulose membranes, which had been blocked with 5%
Marvel in Tris-buffered saline, pH 7.5, at 41C overnight. The
primary antibodies were used at a dilution of 1 : 1000 except for
actin (1 : 200) and myosin (1 : 100), and the secondary antibodies
were also used at a dilution of 1 : 1000. Incubation was for 1 h at
room temperature and development was by enhanced chemilumi-
nescence (ECL) (Amersham, United Kingdom). Blots were scanned
by a densitometer to quantitate differences.
Electrophoresis mobility shift assay
DNA-binding proteins were extracted from myotubes according to
the method of Andrews and Faller (1991), which utilises hypotonic
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Figure 6 Effect of resveratrol on PIF-induced expression of 20S proteasome a-subunits (A), p42 (B), MSS1 (C) and myosin (D) as determined by
Western blotting. An actin loading control is shown in (E). Cells were incubated with 0 (lanes 1 and 6), 2.1 (lanes 2 and 7), 4.2 (lanes 3 and 8), 10.5 (lanes 4
and 9) or 16.8 nM PIF (lanes 5 and 10) in the absence (lanes 1–5) or presence (lanes 6–10) of resveratrol (30 mM) for 24 h. A densitometric analysis of the
three separate Western blots is shown underneath a representative example. Differences from control are indicated as a, Po0.05, b, Po0.01 and c,
Po0.001, while differences in the presence of resveratrol are indicated as d, Po0.05, e, Po0.01 and f, Po0.001.
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lysis followed by high salt extraction of nuclei. The EMSA-binding
assay was carried out using a Panomics EMSA ‘gel shift’ kit
according to the manufacturer’s instructions.
Statistical analysis
Differences in means between groups was determined by one-way
ANOVA, followed by Tukey’s post-test.
RESULTS
To investigate the importance of activation of NF-kB in PIF-
induced proteasome expression and degradation of myofibrillar
proteins in murine myotubes, the cell permeable specific NF-kB
inhibitor SN50 (18 mM) was used to block agonist-induced nuclear
translocation of NF-kB (Lin et al, 1995). At this concentration,
SN50 is not cytotoxic, and there have been no reports that it
interferes with any other signalling pathway. The PIF-induced
increase in 20S proteasome a-subunits seen in the presence of the
inactive congener was not seen in the presence of SN50 (Figure 1A).
Similar results were seen for PIF-induced stimulation of MSS1, an
ATPase subunit of the 19S regulatory complex (Figure 1B), p42, an
ATPase subunit of the 19S regulator that promotes ATP-dependent
association of the 20S proteasome with the 19S regulator to form
the 26S proteasome (Tanahashi et al, 1999) (Figure 1C), and E214k,
one of the major mammalian E2s that support E3a-dependent
ubiquitin conjugate formation (Attaix et al, 1999) (Figure 1D), as
well as the PIF-induced decrease in myosin expression (Figure 1E).
In each case, PIF produced an effect between 2.1 and 10.5 nM,
which was not seen in the presence of SN50. These results suggest
that nuclear translocation of NF-kB is essential for PIF-induced
proteasome expression, ubiquitin conjugation and loss of the
myofibrillar protein myosin.
To evaluate the effect of pharmacological inhibition of NF-kB on
PIF-induced proteasome expression and protein degradation, the
IKK inhibitor curcumin (Thaloor et al, 1999) was employed. At a
concentration of 50mM, curcumin completely attenuated total
protein degradation in murine myotubes at all concentrations of
PIF (Figure 2A). In addition, curcumin attenuated the PIF-induced
increase in ‘chymotrypsin-like’ enzyme activity (Figure 2B), the
predominant proteolytic activity of the proteasome, as well as the
increase in 20S proteasome a-subunits and E214k (Figure 3). These
results suggest that curcumin may be effective in the treatment of
muscle atrophy in cancer cachexia. However, when curcumin was
evaluated in vivo in mice bearing the MAC16 tumour, it was shown
to be ineffective in preventing loss of body weight at dose levels of
150 and 300 mg kg1 (Figure 4). These results prompted us to look
for alternative inhibitors of NF-kB, which may be effective in vivo.
Thus, the effect of another inhibitor of IKK, resveratrol
(Holmes-McNary and Baldwin, 2000) on PIF-induced protein
degradation and proteasome expression was studied in murine
myotubes. At a concentration of 30 mM, resveratrol effectively
attenuated both PIF-induced protein degradation (Figure 5A), as
well as the proteasome chymotrypsin-like enzyme activity
(Figure 5B). Resveratrol also attenuated the PIF-induced increase
in 20S proteasome a-subunit expression (Figure 6A), p42
(Figure 6B), MSS1 (Figure 6C), as well as the decrease in myosin
expression produced by PIF (Figure 6D). To confirm that
resveratrol produced effects on NF-kB at this concentration,
murine myotubes were treated with resveratrol (30 mM) 2 h prior to
the addition of PIF and the effect on I-kBa degradation and nuclear
accumulation of NF-kB was determined (Figure 7). Both PIF-
induced degradation of I-kBa (Figure 7A), and nuclear binding of
NF-kB in response to PIF (Figure 7B) were effectively inhibited by
resveratrol, confirming that the mechanism of action in murine
myotubes was as expected.
To evaluate the anticachectic effect of resveratrol, mice bearing
the MAC16 tumour, and with established weight loss (5%) were
treated with resveratrol (1 mg kg1) daily and the effect on body
weight and tumour volume were determined (Figure 8). Resver-
atrol significantly attenuated weight loss within 24 h of adminis-
tration (Figure 8A) and this was accompanied by inhibition of
tumour growth within 48 h (Figure 6B). In order to determine
whether the increase in body weight in mice treated with
resveratrol resulted from a reduction in protein degradation, the
rate of protein degradation in soleus muscle was determined by the
release of tyrosine (Figure 9). Previous studies (Beck et al, 1991)
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Figure 7 Effect of PIF on I-kBa expression (A) and nuclear translocation
of NF-kB, as determined by EMSA (B) in murine myotubes 30 min after
the addition of PIF. An actin loading control for (A) is shown in (C).
Myotubes were incubated with 0 (lanes 1 and 6), 2.1 (lanes 2 and 7), 4.2
(lanes 3 and 8), 10.5 (lanes 4 and 9) or 16.8 nM PIF (lanes 5 and 10) in the
absence (lanes 1–5) or presence (lanes 6–10) of resveratrol (30 mM). In
(B), lane 12 is a positive control for NF-kB (supplied by the manufacturer
of the kit), while lane 11 contains the positive control for NF-kB together
with a 100-fold excess of unlabelled NF-kB probe. The densitometric
analysis represents three separate experiments. Differences from control
are indicated as b, Po0.01 and c, Po0.001, while differences in the
presence of resveratrol are indicated as e, Po0.01 and f, Po0.001.
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have shown that muscles from mice bearing the MAC16 tumour
have a significant increase in protein degradation compared with
nontumour-bearing controls. Soleus muscle of mice bearing the
MAC16 tumour and treated with resveratrol had a significant
reduction in protein degradation after 48 h treatment compared to
muscles from mice treated with solvent alone (from 9557125 to
56874.5 fluorescent units g1 2 h1, Po0.001, n¼ 12). To verify
that this arose from an effect on nuclear migration of NF-kB, the
amount of NF-kB in the nucleus was determined by EMSA. The
results depicted in Figure 9 show a significant reduction in NF-kB
DNA-binding activity in gastrocnemius muscles of mice treated
with resveratrol. These results suggest that agents which inhibit
nuclear translocation of NF-kB may prove useful in the treatment
of muscle wasting in cancer cachexia.
DISCUSSION
Nuclear factor-kB is involved in the control of a large number of
cellular processes, such as immune and inflammatory responses,
developmental processes, cell growth and apoptosis (Baldwin,
1996). Activation of NF-kB has been connected with tumour cell
survival and proliferation, invasion and angiogenesis, critical
events in tumour metastasis, as well as resistance to chemotherapy
(Baldwin, 2001). Nuclear factor-kB has also been shown to mediate
the protein loss induced by tumour necrosis factor-a (TNF-a) in
differentiated skeletal muscle myotubes (Li and Reid, 2000), and to
be an important transcription factor in PIF-induced proteasome
expression in murine myotubes (Whitehouse and Tisdale, 2003).
Nuclear factor-kB may also be involved in other conditions of
muscle wasting. Thus, hind-limb unloading, a model of disuse
atrophy, resulted in a 10-fold increase in the activity of a
transfected NF-kB-dependent reporter (Hunter et al, 2002), but
this involved p50, c-Rel and Bcl-3 and not activation of p65 or
I-kB, and is thus distinct from cachexia.
This suggests that inhibitors of the release and subsequent
nuclear translocation of NF-kB, or the binding of NF-kB to DNA
should be evaluated as potential agents to prevent muscle atrophy
in cancer cachexia. Agonist-induced nuclear translocation of
NF-kB in intact cells can be inhibited by cell-permeable synthetic
peptides representing the nuclear localisation sequence of NF-kB
(Lin et al, 1995). When such a peptide (SN50) was incubated
together with PIF in murine myotubes it attenuated both the PIF-
induced proteasome expression and the ubiquitin conjugating
enzyme, E214k, as well as the loss of myofibrillar protein myosin.
These results suggest that inhibition of NF-kB activation should
inhibit muscle protein degradation induced by PIF in cancer
cachexia.
Both curcumin and resveratrol, known to be inhibitors of IKK,
attenuated PIF-induced protein degradation in murine myotubes,
as well as the increased expression of the ubiquitin–proteasome
proteolytic pathway. Systemic administration of curcumin
(20mg kg1) has previously been shown not to influence muscle
wasting or changes in body weight in rats bearing the highly
cachectic Yoshida AH-130 ascites hepatoma, although it did reduce
tumour growth (Busquets et al, 2001). In the present study,
curcumin was also unable to reduce weight loss in mice bearing the
MAC16 tumour, even at much higher doses (150 and 300 mg kg1).
This may be due to the low bioavailability (0.06% absorption) (Pan
et al, 1999), which is probably insufficient to exert a therapeutic
effect. Even a dose of 1 g kg1 body weight in the mouse yielded a
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Figure 8 Effect of resveratrol (1 mg kg1 E) on body weight (A) and
tumour volume (B) in mice bearing the MAC16 colon adenocarcinoma
compared with solvent (DMSO : PBS; 1 : 20) controls ( ). The number of
mice in each group, n¼ 6. Differences from control are indicated as b,
Po0.01 and c, Po0.001.
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Figure 9 (A) EMSA of nuclear binding of NF-kB in gastrocnemius
muscle of mice receiving solvent control (lanes 1–6) or resveratrol
(1 mg kg1) (lanes 7–12) after 48 h treatment. Lane 14 is the positive
control for NF-kB and lane 13 is the positive control in the presence of a
100-fold excess of unlabelled NF-kB probe. (B) Densitometric analysis of
the EMSA shown in (A), n¼ 3. Differences from control are shown as c,
Po0.001.
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plasma level of only 0.5 mM (Pan et al, 1999), which is below the
concentration needed to attenuate PIF action in vitro. Resveratrol
(1 mg kg1) was also unable to prevent the loss of body weight in
rats bearing the Yoshida hepatoma, although again it did reduce
tumour growth rate (Carbo´ et al, 1999). In this study, resveratrol at
the same concentration (1 mg kg1) was found to attenuate weight
loss, followed by a reduction in tumour growth rate in mice
bearing the MAC16 tumour, reduce protein degradation in skeletal
muscle, as determined by the release of tyrosine, and reduce
nuclear translocation of NF-kB in gastrocnemius muscle. The
reason for the difference in response to resveratrol in the two
models is not clear. Although TNF-a has been implicated in the
enhanced protein degradation in muscle of rats bearing the
Yoshida ascites hepatoma (Costelli et al, 1993), while in mice
bearing the MAC16 carcinoma PIF appears to be responsible for
the enhanced protein degradation (Lorite et al, 1998), NF-kB has
been shown to mediate the protein loss induced by TNF-a (Li and
Reid, 2000) and thus inhibitors of NF-kB should also be effective in
this model.
Other inhibitors of NF-kB have established or potential roles in
the treatment of cachexia. Thus EPA, which prevents nuclear
migration of NF-kB in murine myotubes in response to PIF by
stabilising the cytosolic I-kB/NF-kB complex (Whitehouse and
Tisdale, 2003), possibly by interfering with I-kB phosphorylation
(Novak et al, 2003), has been shown to attenuate the development
of further weight loss in weight-losing patients with pancreatic
cancer (Wigmore et al, 2000) and produce an increase in lean body
mass when combined with a high protein energy dense nutritional
supplement (Barber et al, 1999). The anti-inflammatory agent,
ibuprofen, has been shown to inhibit constitutive activation of NF-
kB and IKKa in prostate cancer cells (Palayoor et al, 1999), and
when combined with megestrol acetate produced an increase in
body weight in gastrointestinal cancer patients (McMillan et al,
1999), while megestrol acetate alone produced a decrease in body
weight. Another anti-inflammatory agent, thalidomide, can also
block NF-kB activation through inhibition of IKK (Keifer et al,
2001), and has been shown to promote weight gain in HIV-infected
patients receiving treatment for tuberculosis (Reys-Teran et al,
1996), and is currently under evaluation for the treatment of
cancer cachexia. These results suggest that despite the fact that
NF-kB is involved in the control of over 150 target genes (Pahl,
1999), inhibitors of NF-kB activation do not produce overt toxicity
and should be evaluated for the treatment of muscle atrophy in
cancer cachexia.
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